Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

被引:0
作者
Giuseppe Rosano
Piotr Ponikowski
Cristiana Vitale
Stefan D. Anker
Javed Butler
Vincent Fabien
Gerasimos Filippatos
Bridget-Anne Kirwan
Iain C. Macdougall
Marco Metra
Frank Ruschitzka
Vasuki Kumpeson
Udo-Michael Goehring
Peter van der Meer
Ewa A. Jankowska
机构
[1] IRCCS San Raffaele,Department of Medical Sciences, Centre for Clinical and Basic Research
[2] Wroclaw Medical University,Institute of Heart Diseases
[3] University Hospital,Institute of Heart Diseases
[4] Charité Universitätsmedizin,Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin
[5] Baylor Scott and White Research Institute,National and Kapodistrian University of Athens Medical School
[6] University of Mississippi,Department of Clinical Research
[7] CSL Vifor,London School of Hygiene and Tropical Medicine
[8] Athens University Hospital Attikon,Department of Renal Medicine
[9] SOCAR Research SA,Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health
[10] University College London,Department of Cardiology
[11] King’s College Hospital,Department of Cardiology
[12] University of Brescia,undefined
[13] University Heart Center,undefined
[14] University Hospital Zurich and University of Zurich,undefined
[15] University Medical Center Groningen,undefined
来源
Cardiovascular Diabetology | / 22卷
关键词
Diabetes; Acute heart failure; Iron deficiency; Ferric carboxymaltose; AFFIRM-AHF;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 156 条
[1]  
Butt JH(2020)Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort Eur J Heart Fail 22 1777-1785
[2]  
Fosbøl EL(2017)Acute heart failure: epidemiology and socioeconomic burden Cont Cardiol Educ 3 88-92
[3]  
Gerds TA(2022)Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand Eur J Heart Fail 24 1519-1528
[4]  
Andersson C(2021)Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades Eur J Heart Fail 23 420-431
[5]  
McMurray JJV(2010)Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus Am J Cardiol 105 373-377
[6]  
Petrie MC(2009)Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2436-2448
[7]  
Farmakis D(2017)Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry Diabetes Care 40 671-678
[8]  
Papingiotis G(2017)Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the i-preserve trial (irbesartan in heart failure with preserved ejection fraction) Circulation 135 724-735
[9]  
Parissis J(2008)Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme Eur Heart J 29 1377-1385
[10]  
Hariharaputhiran S(2017)In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA heart failure long-term registry Eur J Heart Fail 19 54-65